Supernus Pharmaceuticals, Inc. (SUPN)

In the past six months, Supernus Pharmaceuticals' stock has been influenced by insider sales, congressional trading, Q3 2025 earnings exceeding estimates and raised guidance, the acquisition of Sage Therapeutics, ONAPGO launch with supply constraints, participation in healthcare conferences, and a stock increase of 14.12% over six months and 27.84% over the past year.

Demand for some of Supernus Pharmaceuticals' products, particularly Qelbree for ADHD, is influenced by seasonal patterns, specifically the back-to-school season. The company invests significant effort and resources into this period. Sales of older products like Trokendi XR and Oxtellar XR have experienced declines due to generic competition. The newly launched ONAPGO is experiencing stronger-than-expected demand, but current supply constraints are a more immediate factor than seasonality for this product.

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company specializing in treatments for central nervous system disorders, focusing on unmet medical needs in neurology and psychiatry. Its neuroscience portfolio includes treatments for epilepsy, migraine, ADHD, and Parkinson's Disease. Key products include Qelbree for ADHD, GOCOVRI for Parkinson's disease, Trokendi XR for epilepsy and migraine prophylaxis, Oxtellar XR for partial seizures, APOKYN for Parkinson's disease, XADAGO as an add-on therapy for Parkinson's disease, MYOBLOC for cervical dystonia and chronic sialorrhea, ONAPGO for motor fluctuations in advanced Parkinson's disease, and ZURZUVAE for postpartum depression.

Supernus Pharmaceuticals is headquartered in Rockville, Maryland, and primarily operates through its own sales force in the United States, using partnerships for international markets.

Supernus Pharmaceuticals has an award-winning reputation as a biopharmaceutical company with over 30 years of experience in developing and commercializing CNS disease treatments. The company is recognized for its focus on innovating CNS treatments and improving patient lives through cutting-edge therapies and strategic partnerships. Recent positive developments include the successful launch of ONAPGO and the acquisition of Sage Therapeutics. The company's consistent participation in major healthcare conferences also helps maintain its visibility and engagement with the investment community.

Supernus Pharmaceuticals, Inc. is predominantly owned by institutional investors and passive funds, with institutional ownership exceeding 90%. Major institutional owners include BlackRock Institutional Trust Company, N.A., The Vanguard Group, Inc., Millennium Management LLC, Dimensional Fund Advisors, L.P., Armistice Capital LLC, State Street Corp, Point72 Asset Management, L.P., and Renaissance Technologies LLC. The company's founder, President, and CEO, Jack A. Khattar, also holds a significant individual stake.